Loading...
•
Sep 30, 2021
Royalty Pharma Q3 2021 Earnings Report
Royalty Pharma reported strong growth in the third quarter of 2021, driven by portfolio performance and new royalty acquisitions. The company raised its full-year 2021 guidance for Adjusted Cash Receipts.
Key Takeaways
Royalty Pharma reported a 9% increase in total income and other revenues to $586 million, driven by strong portfolio performance, new royalty acquisitions, and a one-time payment related to Soliqua. Adjusted Cash Receipts increased 24% to $587 million, and Adjusted Cash Flow grew 12% to $441 million.
Net cash provided from operating activities (GAAP) was $470 million.
Adjusted Cash Receipts (non-GAAP) increased 24% to $587 million.
Adjusted Cash Flow (non-GAAP) grew 12% to $441 million.
2021 Adjusted Cash Receipts guidance raised to $2,110 to $2,130 million.
Revenue by Segment
Forward Guidance
Royalty Pharma anticipates 2021 Adjusted Cash Receipts to be between $2,110 million and $2,130 million, excluding new transactions announced after the date of this release. Payments for operating and professional costs will be approximately 9% of Adjusted Cash Receipts in 2021.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...